fig3
![Valve-in-valve transcatheter aortic valve replacement: the challenge of the next future](https://image.oaes.cc/f1414371-6770-49c9-a3dd-e2cac18f723a/4635.fig.3.jpg)
Figure 3. TAVR-in-TAVR after ViV TAVR. A degenerated Carpentier-Edwards Perimount 27 mm bioprosthesis (Edwards Lifesciences, Irvine, California, USA) treated with a first TAVR CoreValve Evolut R 29 mm (Medtronic, Minneapolis, Minnesota, USA) and a subsequent Sapien3 Ultra 26 mm (Edwards Lifesciences, Irvine, California, USA), due to damage to CoreValve leaflets after post-dilation by incomplete expansion with severe aortic regurgitation.